An Alkermes antipsychotic treatment designed to offer the benefits of a commonly prescribed medicine, but without the weight gain side effect, won the backing of an FDA advisory committee on Friday. But even some of the panel members who supported the drug qualified their votes, expressing concern about what the drug could mean for patients taking opioid painkillers.

The vote of the independent panel isn’t binding, but the FDA will consider the body’s votes and comments as it evaluates the drug developed by Dublin, Ireland-based Alkermes (NASDAQ: ALKS), which also maintains operations in Waltham, MA. The agency is expected to… Read more »